Inotec AMD’s NATROX oxygen wound therapy is a simple device that helps diabetic foot ulcers heal.
Patients with diabetes are twice as likely to have peripheral arterial disease (PAD) as those without diabetes.
In the case of wounds, PAD and diabetes will impact the outcomes of treatment, leading to:
- a significantly lower probability of healing
- longer healing times
- higher probability of recurrence
- more chance of wound infection
- greater risk in minor and major amputations
- potentially higher mortality rates.
An obvious way to improve clinical outcomes is to improve blood flow; however, many patients with DFUs are not good candidates for revascularisation surgery due to complications arising from comorbidities, late presentation or chronic ischaemia associated with irreversible tissue injury.
Emerging evidence suggests that topical oxygen therapy may provide a novel solution. The clinical evidence generated so far illustrates that NATROX has a positive effect on healing challenging or non-healing wounds, showing that:
- after eight weeks of treatment for DFUs, 30% of the control group healed, while 90% healed with NATROX
- after less than 25 days of NATROX, 57% DFUs and arterial ulcers healed
- a 53% reduction after eight weeks of NATROX, with seven out of ten DFUs on healing trajectory.
NATROX oxygen wound therapy provides 98% pure humidified oxygen 24/7 directly to the wound bed, while allowing patients to carry on with their everyday life.